Medicine and Dentistry
Pneumothorax
100%
Confocal Laser Scanning Microscopy
100%
Biopsy
100%
Endobronchial Ultrasonography
100%
Transbronchial Biopsy
100%
Liver Metastasis
100%
Lung Alveolus Proteinosis
100%
Thymoma
100%
Fluoroscopy
50%
Computer Assisted Tomography
49%
Ground Glass Opacity
40%
Ascites
33%
Univariate Analysis
20%
Odds Ratio
20%
Bloating
16%
Liver Injury
16%
Inferior Vena Cava
16%
Steroid Therapy
16%
Liver Tumor
16%
Portal Hypertension
16%
Thymectomy
16%
Pneumonectomy
16%
Metastatic Carcinoma
16%
Clinical Finding
12%
Patient Characteristics
10%
Multivariate Logistic Regression Analysis
10%
Division
10%
Final Diagnosis
10%
Multivariate Analysis
10%
Silo-Filler's Disease
10%
Biopsy Sample
6%
Lung Lesion
6%
Disease
6%
Autoantibodies
6%
Alveolar Macrophage
6%
Granulocyte Macrophage Colony Stimulating Factor
6%
Keyphrases
Epidermal Growth Factor Receptor
100%
Immune Checkpoint Inhibitor Therapy
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Programmed Death-ligand 1 (PD-L1)
66%
Immune Checkpoint Inhibitors
66%
EGFR mutation
66%
Combination Therapy
33%
Resistance to Treatment
33%
Tumor-infiltrating Lymphocytes
33%
Chemotherapy
33%
Molecular Targeted Therapy
33%
Treatment Strategy
33%
Therapy Treatment
33%
Severe Toxicity
33%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
33%
Early-stage Lung Cancer
33%
Osimertinib
33%
Tumor Microenvironment
33%
T790M mutation
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
33%
Lung Segment
30%
Extrapleural Pneumonectomy
25%
Albumin Gradient
25%
Pleural Involvement
10%
Left Upper Division
10%
Sagittal Orientation
10%
Patchy Distribution
6%
Tissue Pathology
6%
Amorphous Substance
6%
Disease Intensity
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Programmed Cell Death
40%
Biological Marker
40%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Neoplasm
20%
Osimertinib
20%
Tumor Microenvironment
20%
Combination Therapy
20%
Chemotherapy
20%
Disease
20%
